Abstract
Background: Seizures are common among patients with low-grade glioma (LGG) and can significantly affect morbidity. We sought to determine the association between the clinical and molecular factors with seizure incidence and refractoriness in LGG patients. Methods: We conducted a retrospective review at the University of Virginia in patients with LGG (World Health Organization, WHO Grade II) evaluated between 2002 and 2015. Descriptive statistics were calculated for variables of interest, and the Kaplan-Meier method was used to estimate survival curves, which were compared with the log-rank test. Results: A total of 291 patients were included; 254 had molecular testing performed for presence of an isocitrate dehydrogenase (IDH) mutation and/or 1p/19q codeletion. Sixty-eight percent of patients developed seizures prior to LGG diagnosis; 41% of all patients had intractable seizures. Using WHO 2016 integrated classification, there was no significant difference in seizure frequency during preoperative and postoperative periods or in developing intractable seizures, though a trend toward increased preoperative seizure incidence among patients with the IDH mutation was identified (P =. 09). Male sex was significantly associated with higher seizure incidence during preoperative (P
Author supplied keywords
Cite
CITATION STYLE
Jo, J., Nevel, K., Sutyla, R., Smolkin, M., Lopes, M. B., & Schiff, D. (2021). Predictors of early, recurrent, and intractable seizures in low-grade glioma. Neuro-Oncology Practice, 8(1), 40–47. https://doi.org/10.1093/nop/npaa054
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.